Extensive Experience in XDC Chemical Synthesis
Successfully synthesized a variety of payloads, such as microtubule polymerization inhibitors, DNA binders, etc.
Synthesized a range of cleavable and non-cleavable linkers, including those based on peptides, glucuronides, disulfides, thioethers, PEG, etc.
Advanced XDC Conjugation Technology Platform
Capable of coupling both cleavable and non-cleavable linkers with payloads
Introduces reactive groups that can conjugate with lysine, cysteine, and non-natural amino acids
Comprehensive XDC Drug Evaluation Capabilities
Mastery over a variety of payloads, linkers, and conjugatable “building blocks”
Can design and evaluate the potency, efficacy, pharmacokinetics, and pharmacodynamics properties of candidate XDCs
These small molecule compounds are ready for conjugation with antibodies and peptides to make targeted therapeutics.
A range of payloads have been worked on, covering several mechanisms of action including microtubule polymerization inhibitors and DNA binders.
Pyrrolobenzodiazepines (PBDs), Indolinobenzodiazepine and their derivatives.
Duocarmycins and its derivatives.
Auristatins: MMAE and MMAF.
Camptothecin: Exatecan, Topotecan, Belotecan, SN-38.
PNU-159682
Eribulin
Some other innovative drugs designed by our collaborators
A range of cleavable linkers have been synthesized and used, based around peptides, glucuronides, disulfides and thioethers which are processed intracellularly to release the warhead or payload.
A range of non-cleavable linkers have been synthesized and used, based around peptides, carbohydrate, thioether and PEG components.
These cleavable and non cleavable linkers have been readily attached to payloads or warheads, and have further incorporated reactive conjugatable groups that allow for lysine, cysteine and non-natural amino acid conjugation.
Copyright © Viva Biotech All Rights Reserved. 沪ICP备19036061号